Preprint Communication Version 1 Preserved in Portico This version is not peer-reviewed

Use of the Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs

Version 1 : Received: 1 June 2021 / Approved: 2 June 2021 / Online: 2 June 2021 (16:11:29 CEST)

How to cite: Tan, E.; Frew, E.; Cooper, J.; Humphrey, J.; Holden, M.; Mand, A.R.; Li, J.; Anderson, S.; Bi, M.; Hatler, J.; Person, A.; Mortari, F.; Gould, K.; Barry, S. Use of the Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Preprints 2021, 2021060091 (doi: 10.20944/preprints202106.0091.v1). Tan, E.; Frew, E.; Cooper, J.; Humphrey, J.; Holden, M.; Mand, A.R.; Li, J.; Anderson, S.; Bi, M.; Hatler, J.; Person, A.; Mortari, F.; Gould, K.; Barry, S. Use of the Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Preprints 2021, 2021060091 (doi: 10.20944/preprints202106.0091.v1).

Abstract

Identifying anti-spike antibodies that exhibit strong neutralizing activity against current dominant circulating variants and antibodies that are escaped by these variants have important implications in the development of therapeutic and diagnostic solutions as well as in improving understanding of the humoral response to SARS-CoV-2 infection. We characterized seven anti-RBD monoclonal antibodies for their binding activity, pairing capability and neutralization activity to SARS-CoV-2 and three variant RBDs (UK, SA and BR P.1) via lateral flow immunoassays. The results allowed us to group these antibodies into three distinct epitope bins. Our studies showed that two antibodies had broadly potent neutralizing activity against SARS-CoV-2 and these variant RBDs and that one antibody did not neutralize the SA and BR P.1 RBDs. The antibody escaped by the SA and BR P.1 RBDs retained binding activity to SA and BR P.1 RBDs but was unable to induce neutralization. Further, we demonstrated that the lateral flow immunoassay can be a rapid and effective tool for antibody characterization, including epitope classification and antibody neutralization kinetics. From these studies, the potential contributions of the mutations (N501Y, E484K and K417N/T) contained in these variants’ RBDs on antibody pairing capability, neutralization activity and therapeutic antibody targeting strategy are discussed.

Subject Areas

COVID-19; SARS-CoV-2 variant; lateral flow immunoassay; spike protein; receptor binding domain (RBD); neutralizing antibody; therapeutic antibody cocktail; epitope binning; rapid neutralization test; ACE2

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.